| MeSH term | MeSH ID | Detail |
|---|---|---|
| Persian Gulf Syndrome | D018923 | 1 associated lipids |
| Hemorrhagic Septicemia, Viral | D031941 | 1 associated lipids |
| Pneumonia, Lipid | D011017 | 2 associated lipids |
| Steatorrhea | D045602 | 2 associated lipids |
| Ossification, Heterotopic | D009999 | 2 associated lipids |
| Fasciitis | D005208 | 2 associated lipids |
| Gallbladder Diseases | D005705 | 3 associated lipids |
| Exostoses, Multiple Hereditary | D005097 | 3 associated lipids |
| Simian Acquired Immunodeficiency Syndrome | D016097 | 4 associated lipids |
| Hyperlipoproteinemia Type III | D006952 | 4 associated lipids |
(e,e,e,e)-squalene
(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
Cross Reference
Introduction
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with (e,e,e,e)-squalene?
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
PubChem Associated disorders and diseases
What pathways are associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with (e,e,e,e)-squalene?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with (e,e,e,e)-squalene?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with (e,e,e,e)-squalene
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Van Leusden H and Villee CA | The de novo synthesis of sterols and steroids from acetate by preparations of human term placenta. | 1965 | Steroids | pmid:5857495 |
| Cattel L et al. | Drug design based on biosynthetic studies: synthesis, biological activity, and kinetics of new inhibitors of 2,3-oxidosqualene cyclase and squalene epoxidase. | 1989 Mar-May | Steroids | pmid:2678608 |
| Lewis D et al. | Enzyme inhibition during the conversion of squalene to cholesterol. | 1995 | Steroids | pmid:7482633 |
| Dennick RG | The intracellular organisation of cholesterol biosynthesis. A review. | 1972 | Steroids Lipids Res | pmid:4572325 |
| Abe I | [Bioorganic chemistry of squalene cyclase]. | 1994 | Tanpakushitsu Kakusan Koso | pmid:8090933 |
| Yamamoto S | [Oxidative cyclization of squalene. Biosynthesis of sterols]. | 1970 | Tanpakushitsu Kakusan Koso | pmid:4912088 |
| Corey EJ and Yamamoto H | Correlation of a protosterol from 20,21-dehydro-2,3-oxidosqualene and 2,3-oxidosqualene-sterol cyclase with dihydrolanosterol. | 1970 | Tetrahedron Lett. | pmid:5447652 |
| Rees HH et al. | Cyclization of 2,3-oxidosqualene to cycloartenol in a cell-free system from higher plants. | 1968 | Tetrahedron Lett. | pmid:5640097 |
| Montana M et al. | Safety review: squalene and thimerosal in vaccines. | 2010 Nov-Dec | Therapie | pmid:21176760 |
| Dorea JG | Safety of thimerosal in vaccines: for whom and how many doses? | 2011 Mar-Apr | Therapie | pmid:23189333 |
| Achiraman S et al. | Increased squalene concentrations in the clitoral gland during the estrous cycle in rats: an estrus-indicating scent mark? | 2011 | Theriogenology | pmid:21924481 |
| Alghisi F et al. | Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. | 2011 | Thorax | pmid:21228426 |
| Miettinen TA | Hyperlipoproteinemia--relation to platelet lipids, platelet function and tendency to thrombosis. | 1974 | Thromb. Res. | pmid:4367389 |
| Ali HM et al. | Effects of silencing the RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-cholesterol. | 2014 | Thyroid | pmid:23885719 |
| Chida N and Okamura T | Increased cholesterol-biosynthesis in familial hypercholesterolemia. | 1971 | Tohoku J. Exp. Med. | pmid:5140375 |
| Torinuki W et al. | Effect of beta-carotene on ultraweak chemiluminescence of UVB-irradiated squalene. | 1982 | Tohoku J. Exp. Med. | pmid:7101278 |
| Hayakawa K and Matsuo I | Effects of PUVA therapy on skin surface lipids: skin surface lipid peroxidation in psoriasis vulgaris and its biological significance. | 1986 | Tokai J. Exp. Clin. Med. | pmid:3672560 |
| Yockel S and Schatz GC | Dynamic QM/MM: a hybrid approach to simulating gas-liquid interactions. | 2012 | Top Curr Chem | pmid:21506003 |
| Uchino T et al. | Potent protecting effects of Catuaba (Anemopaegma mirandum) extracts against hydroperoxide-induced cytotoxicity. | 2004 | Toxicol In Vitro | pmid:15046771 |
| Flint OP et al. | Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. | 1997 | Toxicol. Appl. Pharmacol. | pmid:9221828 |
| Kuroda Y et al. | Distinctive patterns of autoimmune response induced by different types of mineral oil. | 2004 | Toxicol. Sci. | pmid:14718649 |
| Sunthornandh P and Ratanabanangkoon K | A comparative study of three vehicles on antibody responses against elapid snake neurotoxin immunogens. | 1994 | Toxicon | pmid:8079368 |
| Johnson WS | Nonenzymic biogenetic-like olefinic cyclizations. | 1967 | Trans N Y Acad Sci | pmid:5237390 |
| Gylling H et al. | Cholesterol synthesis prevails over absorption in metabolic syndrome. | 2007 | Transl Res | pmid:17543849 |
| Siirtola A et al. | Cholesterol absorption and synthesis in pediatric kidney, liver, and heart transplant recipients. | 2006 | Transplantation | pmid:16477216 |
| Moebius FF et al. | Genetic defects in postsqualene cholesterol biosynthesis. | 2000 | Trends Endocrinol. Metab. | pmid:10707051 |
| Laursen AB | [Dangerous adjuvant in swine influenza vaccine]. | 2009 | Ugeskr. Laeg. | pmid:19866499 |
| Bruun Laursen A | [Catastrophic consequences of Pandemrix swine flu vaccine containing squalene]. | 2013 | Ugeskr. Laeg. | pmid:23833781 |
| Mølbak K | [Squalene unlikely sinner]. | 2013 | Ugeskr. Laeg. | pmid:23833782 |
| Ihara T | [Evaluation of alum-adjuvanted whole virus influenza vaccine and future aspects of influenza A (H1N1) 2009 vaccine]. | 2010 | Uirusu | pmid:20848866 |
| Vendt VP | [Studies in the field of chemistry, biochemistry and photobiochemistry of sterols]. | 1975 Sep-Oct | Ukr Biokhim Zh | pmid:1105921 |
| Sanina OL and Datsenko ZM | [Sterol composition of sarcolemma in normal rabbits and in experimental muscular dystrophy]. | 1975 Nov-Dec | Ukr Biokhim Zh | pmid:1202710 |
| PerederiÄ OF and Morozova RP | [Squalene and sterols of rat stomach tissue and the effect of acetylsalicylic acid on their content]. | 1978 Nov-Dec | Ukr. Biokhim. Zh. | pmid:749299 |
| Morozova RP et al. | [Separation of lipid extract from animal blood and tissues and isolation of squalene and sterols from it]. | 1982 Jul-Aug | Ukr. Biokhim. Zh. | pmid:7135500 |
| Dediukhina EG and Eroshin VK | [Hydrocarbon biosynthesis by microorganisms]. | 1973 Nov-Dec | Usp Sovrem Biol | pmid:4593530 |
| Morel S et al. | Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. | 2011 | Vaccine | pmid:21256188 |
| Rouleau I et al. | Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. | 2013 | Vaccine | pmid:24144473 |
| Iorio AM et al. | Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. | 2003 | Vaccine | pmid:12922092 |
| Decaro N et al. | Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. | 2011 | Vaccine | pmid:21272607 |
| Calabro S et al. | Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. | 2011 | Vaccine | pmid:21215831 |
| Javelle E et al. | Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. | 2011 | Vaccine | pmid:21172376 |
| Singh M et al. | A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. | 2006 | Vaccine | pmid:16300864 |
| Esposito S et al. | Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. | 2011 | Vaccine | pmid:21199699 |
| Puig-Barberà J et al. | Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. | 2004 | Vaccine | pmid:15530669 |
| O'Hagan DT et al. | Cationic microparticles are a potent delivery system for a HCV DNA vaccine. | 2004 | Vaccine | pmid:15542189 |
| Pellegrini M et al. | MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. | 2009 | Vaccine | pmid:19751689 |
| Del Giudice G et al. | An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. | 2006 | Vaccine | pmid:16464520 |
| Barnett SW et al. | Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. | 1997 | Vaccine | pmid:9234536 |
| Forrest HL et al. | Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. | 2009 | Vaccine | pmid:19406182 |
| Camilloni B et al. | Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. | 2009 | Vaccine | pmid:19410623 |
| Byars NE and Allison AC | Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. | 1987 | Vaccine | pmid:3499713 |
| Schultze V et al. | Safety of MF59 adjuvant. | 2008 | Vaccine | pmid:18462843 |
| Boyce TG et al. | Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. | 2000 | Vaccine | pmid:10930676 |
| O'Hagan DT et al. | Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. | 2000 | Vaccine | pmid:10699327 |
| Keitel W et al. | Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. | 2010 | Vaccine | pmid:19835829 |
| Vesikari T et al. | MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. | 2009 | Vaccine | pmid:19840662 |
| Hilgers LA et al. | A novel non-mineral oil-based adjuvant. I. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in laboratory animals. | 1994 | Vaccine | pmid:8085385 |
| Hilgers LA et al. | A novel non-mineral oil-based adjuvant. II. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in pigs. | 1994 | Vaccine | pmid:8085386 |
| Byars NE et al. | Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. | 1994 | Vaccine | pmid:8165851 |
| Ansaldi F et al. | Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. | 2010 | Vaccine | pmid:20433807 |
| Precioso AR et al. | A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. | 2011 | Vaccine | pmid:21945258 |
| Pariani E et al. | Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. | 2011 | Vaccine | pmid:21974995 |
| Andrews NJ et al. | Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. | 2011 | Vaccine | pmid:21875635 |
| Iorio AM et al. | Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. | 2012 | Vaccine | pmid:22245606 |
| Dupuis M et al. | Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. | 1999 | Vaccine | pmid:10519932 |
| Ott G et al. | Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. | 1995 | Vaccine | pmid:8578842 |
| Heineman TC et al. | A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. | 1999 | Vaccine | pmid:10438046 |
| De Donato S et al. | Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. | 1999 | Vaccine | pmid:10462245 |
| Higgins DA et al. | MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. | 1996 | Vaccine | pmid:8782343 |
| Minutello M et al. | Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. | 1999 | Vaccine | pmid:9987141 |
| Hilgers LA et al. | Sulfolipo-cyclodextrin in squalane-in-water as a novel and safe vaccine adjuvant. | 1999 | Vaccine | pmid:9987157 |
| Tsai T et al. | Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. | 2010 | Vaccine | pmid:19969117 |
| Pietrella D et al. | A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. | 2010 | Vaccine | pmid:20038431 |
| Langley JM et al. | Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. | 2012 | Vaccine | pmid:22469860 |
| Fukase H et al. | Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. | 2012 | Vaccine | pmid:22472791 |
| Camilloni B et al. | An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. | 2010 | Vaccine | pmid:20846530 |
| Hatz C et al. | A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. | 2012 | Vaccine | pmid:22446638 |
| Fabbiani M et al. | Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. | 2011 | Vaccine | pmid:21349364 |
| O'Hagan DT et al. | The mechanism of action of MF59 - an innately attractive adjuvant formulation. | 2012 | Vaccine | pmid:22682289 |
| Yu S et al. | Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice. | 2012 | Vaccine | pmid:22709954 |
| Della Cioppa G et al. | Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. | 2011 | Vaccine | pmid:21906647 |
| Moro ML et al. | A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two. | 2013 | Vaccine | pmid:22885015 |
| Fox CB et al. | Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. | 2011 | Vaccine | pmid:21906648 |
| Radosević K et al. | Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. | 2008 | Vaccine | pmid:18514980 |
| Brito LA et al. | An alternative renewable source of squalene for use in emulsion adjuvants. | 2011 | Vaccine | pmid:21723355 |
| Puig-Barberà J et al. | Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. | 2007 | Vaccine | pmid:17889411 |
| Chandramouli S et al. | Generation of a parvovirus B19 vaccine candidate. | 2013 | Vaccine | pmid:23827313 |
| Black S et al. | Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. | 2010 | Vaccine | pmid:20813217 |
| Madhun AS et al. | An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. | 2010 | Vaccine | pmid:21034828 |
| de Bruijn I et al. | Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. | 2007 | Vaccine | pmid:18063446 |
| Wack A et al. | Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. | 2008 | Vaccine | pmid:18162266 |
| Tetsutani K and Ishii KJ | Adjuvants in influenza vaccines. | 2012 | Vaccine | pmid:23084848 |
| Nielsen AB et al. | Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. | 2012 | Vaccine | pmid:23036498 |
| Cristiani C et al. | Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district. | 2011 | Vaccine | pmid:21396903 |
| Meier S et al. | Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. | 2011 | Vaccine | pmid:21419775 |
| Parretta E et al. | Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. | 2011 | Vaccine | pmid:21406267 |
| Garcia-Sicilia J et al. | Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. | 2011 | Vaccine | pmid:21504774 |
| Van Buynder PG et al. | The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. | 2013 | Vaccine | pmid:23933368 |
| Vinay TN et al. | Inactivated vaccine against viral hemorrhagic septicemia (VHS) emulsified with squalene and aluminum hydroxide adjuvant provides long term protection in olive flounder (Paralichthys olivaceus). | 2013 | Vaccine | pmid:23896420 |
| Poder A et al. | An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age. | 2014 | Vaccine | pmid:24252703 |